Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Neoadjuvant androgen suppression therapy (AST) prior to brachytherapy and risk of death in men with favorable risk prostate cancer and pre-existing cardiovascular comorbidity

Neoadjuvant androgen suppression therapy (AST) prior to brachytherapy and risk of death in men with favorable risk prostate cancer and pre-existing cardiovascular comorbidity. Genitourinary Cancers Symposium. 2009; 102.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.